CFTR and cystic fibrosis: As a result, more than 90% of cystic fibrosis patients are now genetically eligible for modulator therapies, and the list of CFTR variants responsive to ETI is continuously expanding through patient-derived models, such as intestinal organoids [35,36] and airway epithelial cells [37,38] which closely mimic native patient tissues [39,40,41].